country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-N5040

Copy Link Print Information

Ilexhainanoside D

Name: Ilexhainanoside D
Brand: MedChemExpress
SKU: HY-N5040
Price: 78.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Customer Review

Based on 1 Customer Validation

Ilexhainanoside D is the main triterpenoid saponin extracted from Ilex hainanensis Merr., and the combination of Ilexhainanoside D and ilexsaponin A1 has anti-inflammation effect.

For research use only. We do not sell to patients.

Purity : 99.53%
CAS No.: 1137648-52-2
Formula: C₃₆H₅₆O₁₁
Molecular Weight:664.82

Storage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ilexhainanoside D Chemical Structure

CAS No.: 1137648-52-2

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

HY-N3010
Salviaflaside

Phenolic Glycoside

Biological Activity
- Description
- In Vivo
Chemical Information
Protocols (1)
Purity & Documentation
References
Calculators
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Ilexhainanoside D is the main triterpenoid saponin extracted from Ilex hainanensis Merr., and the combination of Ilexhainanoside D and ilexsaponin A1 has anti-inflammation effect^[1].

In Vivo

The combination of Ilexhainanoside D and Ilexsaponin A (60, 120 or 240 mg/kg; for 8 weeks) treatment significantly reduces the severity of non-alcoholic fatty liver disease (NAFLD) induced by high-fat diet in a dose-dependent manner. The combination of Ilexhainanoside D and Ilexsaponin A treatment decreases the ratio of Firmicutes/Bacteroidetes, reduces the relative abundance of Desulfovibrio and increases the relative abundance of Akkermansia. The intestinal barrier is improved as evidenced by the upregulation of the expression of zonula occludens-1 (ZO-1) and occludin in the ileum. The combination of Ilexhainanoside D and Ilexsaponin A treatment reduces the entry of LPS into the circulation and decreases the hepatic gene expression levels of proinflammatory cytokines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1137648-52-2
Appearance Solid
Molecular Weight 664.82
Formula C₃₆H₅₆O₁₁
Color White to off-white
SMILES

OC[C@H]([C@@H](O)[C@H](O)[C@H]1O)O[C@H]1OC([C@]23[C@]([C@@H](C(C)(C)CC3)O)([H])C4=CC[C@@]([C@@]5([C@@]([C@](C)([C@@H](O)CC5)C(O)=O)([H])CC6)C)([H])[C@]6(C)[C@]4(C)CC2)=O
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Protocols

All Signal Pathway Related

Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhao W, et al. The combination of Ilexhainanoside D and ilexsaponin A1 reduces liver inflammation and improves intestinal barrier function in mice with high-fat diet-induced non-alcoholic fatty liver disease. Phytomedicine. 2019 Jul 26;63:153039. [Content Brief]

Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Get Quote In-stock

Other size

Get Quote